Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 September 2021 | Story Nonsindiso Qwabe
“This way please” UFS Clinic nurses point the way. From left to right: Sister Nangamso Lukhubeni, Sister Noluthando Luthuli, Sister Mathapelo Moloi, and Sister Modiehi Moloi.

Fully vaccinated! 

These were the words uttered by many Qwaqwa staff members who received their second Pfizer jab at the vaccination site on the Qwaqwa Campus on Thursday (2 September 2021). More than 100 staff members turned up at the site, many for the second jab, while others were there to get their first. The staff members were full of praise for the convenience of having a site on campus, and said the brisk service made the entire process a breeze. The 24/7 Study Centre on campus was repurposed as a vaccination site at the end of August, bringing much-needed relief to staff and students, as well as the Qwaqwa community.

The vaccination experience

Chelly König, Professional Officer in the Department of Chemistry, urged people to trust the science behind the vaccine and the fact that it works. König also came with her relatives. “I’m fully vaccinated and feeling fantastic. I’d urge anyone who’s still hesitant to trust the sciences; these people know what they are doing. My aunt, who is 62, developed COVID-19 after getting her two jabs, and she didn’t experience any effects at all. It was just like the flu. Seeing her recovery convinced me that the vaccine works.”

Ntswaki Mokoena of Bidvest Prestige Cleaning Services also received her second jab. She said: “I am fully vaccinated and so happy. I’ve experienced no side effects whatsoever, and I encourage people to vaccinate; the vaccine is harmless. They should not listen to naysayers who haven’t even vaccinated.”

Calling on more people to vaccinate 

Sister Mathapelo Moloi, Chief Officer at the campus clinic, said the vaccination drive was a source of pride for the campus. “Our priority is to re-open the campus, so I’m very happy that we are seeing staff and students being willing to get vaccinated.”

“It’s not the first time that there has been hesitancy around the vaccine. Providing information is our priority – to help them understand the side effects and everything pertaining to the vaccine.”

Acting Director of Student Affairs on Qwaqwa Campus, Zakhele Mdluli, said vaccinations would help the university community get back to normal. “I encourage students to get vaccinated so that they are able to come back to campus knowing that everyone is safe. This vaccination is no different from the vaccinations we used to get when we were younger.”

The centre operates Monday to Friday from 08:00 to 15:00. People can pre-register either online at https://vaccine.enroll.health.gov.za or via WhatsApp on +27 0 60 012 3456 and should bring along their identity documents. The site is open to anyone 18 years and older. They can simply walk in – no bookings are required.”

News Archive

Nobel Prize-winner presents first lecture at Vice-Chancellor’s prestige lecture series
2017-11-17


 Description: Prof Levitt visit Tags: Prof Levitt visit

At the first lecture in the UFS Vice Chancellor’s Prestige Lecture series,
were from the left: Prof Jeanette Conradie, UFS Department of Chemistry;
Prof Michael Levitt, Nobel Prize-winner in Chemistry, biophysicist and
professor in structural biology at Stanford University; Prof Francis Petersen,
UFS Vice-Chancellor and Rector; and Prof Corli Witthuhn,
UFS Vice-Rector: Research. 
Photo: Johan Roux

South African born biophysicist and Nobel Prize-winner in Chemistry, Prof Michael Levitt, paid a visit to the University of the Free Sate (UFS) as part of the Academy of Science of South Africa’s (ASSAf) Distinguished Visiting Scholars’ Programme. 

Early this week the professor in structural biology at Stanford University in the US presented a captivating lecture on the Bloemfontein Campus on his lifetime’s work that earned him the Nobel Prize in 2013. His lecture launched the UFS Vice-Chancellor’s Prestige Lecture series, aimed at knowledge sharing within, and beyond our university boundaries. 

Prof Levitt was one of the first researchers to conduct molecular dynamics simulations of DNA and proteins and developed the first software for this purpose. He received the prize for Chemistry, together with Martin Karplus and Arieh Warshel, “for the development of multiscale models for complex chemical systems”.

Attending the lecture were members of UFS management, academic staff from a range of faculties and other universities as well as young researchers. “Multiscale modelling is very much based on something that makes common sense,” Prof Levitt explained. “And that is to makes things as simple as possible, but not simpler. Everything needs to have the right level of simplicity, that is not too simple, but not too complicated.”  

An incredible mind
Prof Levitt enrolled for applied mathematics at the University of Pretoria at the age of 15. He visited his uncle and aunt in London after his first-year exams, and decided to stay on because they had a television, he claims. A series on molecular biology broadcast on BBC, sparked an interest that would lead Prof Levitt via Israel, and Cambridge, to the Nobel Prize stage – all of which turned out to be vital building blocks for his research career. 

Technology to the rescue
The first small protein model that Prof Levitt built was the size of a room. But that exercise led to the birth of multiscale modelling of macromolecules. For the man on the street, that translates to computerised models used to simulate protein action, and reaction. With some adaptations, the effect of medication can be simulated on human protein in a virtual world. 

“I was lucky to stand on the shoulder of giants,” he says about his accomplishments, and urges the young to be good and kind. “Be passionate about what you do, be persistent, and be original,” he advised.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept